APM
NGNE icon

Avidity Partners Management’s Neurogene NGNE Stock Holding History

Avidity Partners Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-425,041
Closed -$17.8M – 76
2024
Q3 		$17.8M Sell
425,041
-302,496
-42% -$11.7M 0.91% 42
2024
Q2 		$26.5M Buy
727,537
+262,300
+56% +$9.25M 1.13% 38
2024
Q1 		$23.7M Sell
465,237
-1,006
-0.2% -$33.6K 0.76% 45
2023
Q4 		$9.04M Buy
+466,243
New +$6.68M 0.33% 62
2020
Q1 		– Sell
-10,500
Closed -$2.59M – 60
2019
Q4 		$2.59M Buy
+10,500
New +$1.05M 1.63% 27

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Avidity Partners Management's NGNE Position: Q4 2024 in Review

Avidity Partners Management sold out of Neurogene (NGNE) in Q4 2024, closing a stake of 425,041 shares — an estimated $17.8M sold.

Avidity Partners Management first reported a position in NGNE in Q4 2019 and held it in 5 quarters. The position peaked at $26.5M in Q2 2024. 88 funds tracked by Wall St. Rank hold NGNE as of Q4 2024.

  • Avidity Partners Management reported no remaining Neurogene position as of Q4 2024 after selling out during the quarter.
  • Avidity Partners Management sold 425,041 Neurogene shares in Q4 2024, an estimated $17.8M.
  • Avidity Partners Management first reported a position in Neurogene in Q4 2019 and held it in 5 quarters.
  • Avidity Partners Management's Neurogene position peaked at $26.5M in Q2 2024.
  • 88 funds tracked by Wall St. Rank held Neurogene as of Q4 2024.

Based on Avidity Partners Management's 13F filing for Q4 2024, filed 14 Feb 2025.